Recombinant Capital Presents
ALLICENSE 2001
PARTNERING AFTER THE BOOM:
WHO’S CALLING THE SHOTS NOW
May 22 & 23, 2001
Fairmont Hotel, San Francisco, CA
Program Agenda (As of: May 9 , 2001)
All Speakers Confirmed
Tuesday, May 22
8:00 – 9:45
Session 1: Building a Major Pharmaceutical R&D Pipeline Via Alliances:
* Session Chair: Pamela R. Demain, Executive Director, Corporate Licensing, Merck & Co.
* R. Christopher Seaton, Senior Vice President, Global Licensing, Bayer Corporation
* Elmar Konz, Ph.D., Head of Technology Licensing and Alliances, Aventis Pharma
* Steve Holtzman, Chief Business Officer, Millennium Pharmaceuticals
* Christopher McLeod Executive Vice President, Curagen
Morning Break 9:45 – 10:15
10:15 – 12:00
Session 2: Broadbased Collaborations -- Negotiating and Managing Major Alliances:
* Session Chair: Stelios Papadopoulos, Ph.D., Managing Director, S.G. Cowen Securities Corporation
* Victor Hartmann, Head of Global Business Development and Licensing, Novartis Pharma
* Joshua Boger, Ph.D., Chairman & CEO, Vertex Pharmaceuticals
* Scott Foraker, Vice President, Licensing, Amgen
* Bruce Carter, Ph.D., Chief Executive Officer, ZymoGenetics
Luncheon 12:00 – 1:00
1:00 – 2:45
Session 3: Technology-Based Alliances – Building Successful Non-exclusive Relationships
* Session Chair: Lita Nelsen, Director, Technology Licensing Office, MIT
* Ravi Kiron, Director of Strategic Alliances, Pfizer
* Peter Barrett, EVP & Chief Business Officer, Celera Genomics
* Robert Kirkman, Vice President, Business Development, Protein Design Labs
* Ray Withy, President & COO, Abgenix
Afternoon Break 2:45 - 3:15
3:15 – 5:00
Session 4: Creating and Sustaining Alliance Portfolios:
* Session Chair: Tamar Howson, Special Limited Partner, Care Capital, LLC
* David E. Thompson, Vice President, Corporate Business Development, Eli Lilly
* Tom Heyman, Executive Vice President, Business Development, Johnson & Johnson
* Vaughn Kailian, Chief Executive Officer, COR Therapeutics
* Patrick J. Ashe, Vice President, Commercial Development, Elan Corporation
.......................................................................
ALLICENSE 2001 BREAKTHROUGH ALLIANCE AWARDS DINNER
6.30PM IN THE VENETIAN ROOM
.......................................................................
Wednesday, May 23
8:00 – 9:45
Session 5: Partnering with a New Generation of Pharmas and Biotechs
* Session Chair: Dr. Maria Freire, Director, Office of Technology Transfer, NIH
* Harold H. Shlevin, Ph.D., President & CEO, Solvay Pharmaceuticals
* Kees Been, Vice President of Business & Market Development, Biogen
* Brad Margus, Chief Executive Officer, Perlegen Sciences
* William Matthews, Ph.D., Chief Executive Officer, Deltagen
Morning Break 9:45 – 10:15
10:15 – 12:00
Session 6: Making a Business out of Alliances – What’s Around the Corner?
* Session Chair: Ronald A. Pepin, Ph.D., Vice President of Business Development, Medarex
* Bruce Cozadd, Executive Vice President and COO, ALZA Corporation
* Mark L. Lee, Ph.D., Vice President Worldwide Licensing, Wyeth-Ayerst Pharmaceuticals
* Paul Clark, President & CEO, ICOS Corporation
* Peter Wirth, Executive Vice President, Genzyme Corporation
Luncheon 12:00 – 1:00
1:00 – 2:30
Session 7: Case Study: Partnering When You Need to Keep Some Rights at Home
* Joseph McCracken, Vice President, Business Development, Genentech
* Mark Wiggins, Vice President, Business Development & Marketing, IDEC Pharmaceuticals
* Geoff Cooper, Ph.D., Vice President, Business Development, OSI Pharmaceuticals
Afternoon Break 2:30 – 3:00
3:00 – 4:30
Session 8: Vexing Issues from the Negotiation Table – A Roundtable Discussion
* Mark Edwards, Managing Director, Recombinant Capital
* Kees Been, Vice President of Business & Market Development, Biogen
* Steve Holtzman, Chief Business Officer, Millennium Pharmaceuticals
* Peter Wirth, Executive Vice President, Genzyme Corporation
* Joseph McCracken, Vice President, Business Development, Genentech
* Ronald A. Pepin, Ph.D., Vice President of Business Development, Medarex
~Cocktail Reception 4:30 – 6:00~
|